(redirected from Ultrasound Contrast Agent)
UCAUniversity of Central Arkansas
UCAUniversidad de Cádiz (Spain)
UCAUniversidad Católica Argentina
UCAUniversal Common Ancestry (evolutionary theory)
UCAUniting Church in Australia
UCAUniversal Cheerleaders Association
UCAUniversity for the Creative Arts (UK)
UCAUnicode Collation Algorithm
UCAUpper Control Arm
UCAUnited Computer Accessories
UCAUnited Computer Associates
UCAUnicast Address
UCAUnder Color Addition
UCAUniversity of Central Asia
UCAUrban Conservation Area (various locations)
UCAUniversity of Central America
UCAUndefinitized Contract Action
UCAUtility Communications Architecture
UCAUndercover Agent
UCAUtah Code Annotated
UCAUniform Credit Analysis
UCAUnion Collective Agreement
UCAUltrasound Contrast Agent (imaging)
UCAUniform Circular Array
UCAUndefinitized Contractual Action
UCAUnauthorized Computer Access (Japan)
UCAUniform Chart of Accounts
UCAUnited Colonial Army (Killzone)
UCAUniversità degli Studi di Cagliari
UCAUtica, NY, USA - Oneida County (Airport Code)
UCAUnit Climate Assessment (USAF)
UCAUnsupported Credit Approval (UK)
UCAUnified Cryptologic Architecture (NSA)
UCAUndefinitized Contract Authorization
UCAUnternehmer Consult Ag (Munich, Germany)
UCAUse Case Analysis
UCAUnion des Conservateurs d'Aquariums (French: Union of Aquarium Conservators)
UCAUnit Career Advisor
UCAUganda Co-Operative Alliance Limited
UCAUltraclean Air
UCAUniversity Cheerleaders Association
UCAU-matic Cassette Application
UCAUniform Cost Accounting
UCAUxbridge Conservation Association (Canada)
UCAUniversity Counselling Association
UCAUser Computer Address
UCAUnder Construction Always
UCAUnpriced Contract Action (USACE)
UCAUpper Close Auxiliary
References in periodicals archive ?
com)-- Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer.
M2 PHARMA-October 12, 2015-Bracco Diagnostics Ultrasound Contrast Agent Approved by The Centers for Medicare and Medicaid
Ultrasound contrast agent was SonoVue (Bracco), which were microbubbles of the phospholipids microencapsulated sulfur hexafluoride (SF [sub]6 ).
A microbubble ultrasound contrast agent is widely used as contrast media in ultrasonography, yet it is acts as a cavitation nuclei or enhancer.
IMCOR is a specialty pharmaceutical company developing and marketing innovative imaging products including Imagent, its current ultrasound contrast agent.
OB) closed the previously announced transaction whereby Photogen has acquired all of the assets of Alliance related to medical imaging, including all manufacturing and marketing rights to Imagent(R) (formerly Imavist(TM)), Alliance's ultrasound contrast agent that was approved by the FDA for marketing in the United States in June 2002.
Imavist(TM), an ultrasound contrast agent awaiting final FDA approval, is being developed jointly by Alliance and Schering AG, Germany, and will be marketed in the U.
A laboratory-scale method of producing micron-sized hollow microcapsules from a biodegradable polymer such as 50/50 poly(D,L-lactide-co-glycolide) (PLGA), for use as a diagnostic ultrasound contrast agent, was developed.
The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging.
San Diego, CA) announced that the companies have entered into a non-exclusive, cross-licensing agreement covering ultrasound contrast agent patents.
Full browser ?